Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA7 | P43166 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12143438 | 0.87 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL20295092 | 0.85 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL19500263 | 0.85 | SLC7A5 (0.44) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL14081424 | 0.84 | LOXL2 (0.69) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL20295184 | 0.84 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL27405488 | 0.83 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL20295195 | 0.83 | CYP4F2 (0.69) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL43683 | 0.82 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL7474110 | 0.82 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL1311719 | 0.81 | LOXL2 (0.70) | NPC1RAB9ASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944654-B2 | Nargenicin compounds and uses thereof as antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944654-B2 | Nargenicin compounds and uses thereof as antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170305924-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305924-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| US-8580822-B2 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120252842-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-8247563-B2 | 5,6-dimethoxy-2-(piperidin-4-ylmethyl)-2,3-dihydro-1H-inden-1-one ; for therapy of Alzheimer's disease, myasthenia gravis, Huntingtons disease or glaucoma | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-7951813-B2 | Aldehyde dehydrogenase; 3-(4-hydroxyphenyl)-7-[(5-phenyl(1,2,4-oxadiazol-3-yl))methoxy]-3-hydroquinazolin-4-one; alcoholism; cocaine and nicotine addictions | GILEAD SCIENCES, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| CN-101626688-A | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS INC | 2010-01-13 | — | — | CN | disclosed |
| EP-2129665-A1 | QUINAZOLINONE DERIVATIVES AS ALDH-2 INHIBITORS | CV Therapeutics Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| EP-2114166-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | Reviva Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008124532-A1 | QUINAZOLINONE DERIVATIVES AS ALDH-2 INHIBITORS | CV THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249116-A1 | QUINAZOLINONE DERIVATIVES AS ALDH-2 INHIBITORS | AMYGDALA NEUROSCIENCES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080153878-A1 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| WO-2008073452-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305924-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | NRDC, MME, NME2 | NPC1 583/4885RAB9A 2194/4885SMN1; SMN2 4298/4885 |
| US-20080249116-A1 | QUINAZOLINONE DERIVATIVES AS ALDH-2 INHIBITORS | ALDH1A1, ALDH2, ALDH3A1 | NPC1 1674/4885RAB9A 2264/4885SMN1; SMN2 2564/4885 |
| US-20080153878-A1 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | ACHE, BCHE, CHKA | NPC1 584/4885RAB9A 3786/4885SMN1; SMN2 2821/4885 |
| US-20120252842-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | ACHE, BCHE, CHKA | NPC1 584/4885RAB9A 3786/4885SMN1; SMN2 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.